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Macroporous scaffolds made of a SiO2-CaO-P2O5 mesoporous bioactive glass (MBG) and ɛ-
polycaprolactone (PCL) have been prepared by robocasting. These scaffolds showed an excellent in 
vitro biocompatibility in contact with osteoblast like cells (Saos 2) and osteoclasts derived from 
RAW 264.7 macrophages. In vivo studies were carried out by implantation into cavitary defects 
drilled in osteoporotic sheep. The scaffolds evidenced excellent bone regeneration properties, 
promoting new bone formation at both the peripheral and the inner parts of the scaffolds, thick 
trabeculae, high vascularization and high presence of osteoblasts and osteoclasts. In order to 
evaluate the effects of the local release of an antiosteoporotic drug, 1% (%wt) of zoledronic acid 
was incorporated to the scaffolds. The scaffolds loaded with zoledronic acid induced apoptosis in 
Saos 2 cells, impeded osteoclast differentiation in a time dependent manner and inhibited bone 
healing, promoting an intense inflammatory response in osteoporotic sheep. 
 







Osteoporosis has been defined as “a systemic disease characterized by low bone mass and micro-
architectural deterioration of bone tissue, with consequent increase in bone fragility and 
susceptibility to fracture” [1] and it is associated with significant morbidity and mortality [2,3]. 
Osteoporosis also hinders the clinical success of endosseous implants and grafting materials for the 
treatment of bone defects [4]. The systemic metabolism and the site morphological conditions make 
difficult not only the primary stability, but also biological fixation, osteointegration and bone 
regeneration processes [5,6]. 
Mesoporous bioactive glasses (MBGs) are a group of bioceramics that have arisen great interest in 
the field of regenerative medicine of bone [7,8] and for local drug delivery purposes [9,10]. These 
materials combine the bone regenerative properties of bioactive glasses [11,12] with the high 
surface area and porosity of silica based mesoporous materials [13]. The synergy between chemical 
composition and textural properties of MBGs results in bone grafts with excellent bioactive 
behavior under both in vitro [14–16] and in vivo [17,18] conditions. In combination with 
biocompatible polymers, MBGs can be fabricated as scaffolds for bone tissue regeneration purposes 
[19-21], resulting in porous structures that exhibit excellent biocompatibility, good  differentiation 
markers activities and capability to host osteogenic agents. Some studies suggest that the presence 
of MBGs enhances the mechanical properties of macroporous structures [22,23].  
Robocasting method (also referred as 3D printing) has been widely used for manufacturing MBG 
based scaffolds with highly regular and interconnected macroporosity [24-29].  Among 
biocompatible polymers, -polycaprolactone (-PCL) has shown very interesting features, 
especially when is manufactured as 3D scaffolds using additive manufacturing techniques [30-32]. 
More specifically, -PCL has been widely used as continuous phase for MBG-PCL composites 
manufactured by robocasting, as -PCL exhibits plastic properties that facilitate its processing by 




a binder, supplying the required rheological characteristics for the obtention of structural stability of 
the struts and layers during the printing. Besides, the robocasting of MBG-PCL mixtures produces 
scaffolds with uniform pore structures able to stimulate the cell colonization by enhancing 
osteoblast proliferation and differentiation [37], thus being excellent candidates for bone grafting 
purposes, even in osteoporotic patients. However, no in vivo evidence has been provided about the 
real potential of this combination. 
The association of drugs with bone grafting materials has provided very positive outcomes for the 
treatment of bone defects [38-40]. In this sense, zoledronic acid is an antiresorptive bisphosphonate 
that inhibits the osteoclastic activity, increases mineral bone density (MBD), enhances compression 
strength of bone and significantly decreases the risk of fractures. Based on these clinical outcomes, 
several authors have proposed the incorporation of zoledronic acid in bone grafts, with the aim of 
improving the outcomes of several biomaterials in bone healing processes [41-48]. However, 
administration of zoledronic acid leads to a decrease of bone remodeling markers, including those 
associated to bone formation such as collagen type I and alkaline phosphatase [49]. Besides, it has 
been suggested, but not demonstrated, that zoledronic acid interferes with the reparative 
mechanisms of bone and leads to adynamic bone disease [42]. Identifying the positive or 
deleterious effects of zoledronic acid on bone regeneration requires in vivo studies in appropriated 
animal models. These studies should simulate the osteoporosis conditions in humans, using 
biomechanically relevant animal models.  
The main aim of this work has been the preparation of MBG-PCL macroporous scaffolds for bone 
regeneration in an osteoporotic sheep model. In order to determine the beneficial or deleterious 
effect of zoledronic acid incorporated to these scaffolds. To achieve these aims, highly bioactive 
MBG-PCL macroporous scaffolds were designed and fabricated by robocasting and implanted in 




comparable to human osteoporosis in terms of osteoporosis degree, deterioration of trabecular 
structure, bone metabolism, hormone profile and anatomy [50–53]. 
2. Materials and methods 
2.1. Synthesis of mesoporous bioactive glass MBG-58S 
Mesoporous bioactive glass MBG-58S with composition 58 SiO2 - 37 CaO - 5 P2O5 (% mol) was 
synthesized by evaporation induced self-assembly (EISA) process [54,55], using the  nonionic 
surfactant Pluronic F127 as structure directing agent. F127 (2 g) were dissolved in 38 g of ethanol 
with 1 mL of 0.5 M HCl solution. Afterwards, 3.75 mL of tetraethyl orthosilicate (TEOS), 0.44 mL 
of triethyl phosphate (TEP) and 2.47 g of Ca(NO3)2·4H2O were added under continuous stirring in 3 
h intervals. The obtained sols were cast in Petri dishes (9 cm diameter) to undergo the EISA process 
at 30 °C for 7 days in Petri dishes and the resulting gels were treated at 700 °C for 3 h to obtain the 
final MBG-58S as a calcined glass powder. The powder was sieved and the particles size fraction 
between 25 and 40 micrometers was collected. All reactants were purchased from Sigma-Aldrich 
and used without further purification. 
2.2. Preparation of mesoporous bioactive glass/-polycaprolactone (MBG-PCL) scaffolds 
-polycaprolactone (3 g) of Mw = 58,000 Da (Sigma-Aldrich) were dissolved in 40 mL of 
dichloromethane. Subsequently 4.5 g of MBG-58S suspended in 37.5 mL of dichloromethane were 
incorporated to this solution and mixed until obtaining a homogeneous suspension. In order to 
facilitate the extrusion of this mixture through our robotic deposition apparatus, the solvent was 
partially evaporated for 2 hours at room temperature until obtaining around 10 ml of a viscous 
paste. For comparison purposes, scaffolds containing zoledronic acid (MBG-PCL-zol) were 
prepared including 75 mg of zoledronic acid (United States Pharmacopeia, USP, Reference 
Standard) in the mixture, which correspond to 1 % in weight. In human adults, zoledronic acid is 




weight of each scaffold is about 415 mg, we decided to incorporate 1% in weight, i.e. 4.15 mg of 
zoledronic acid, similarly to the dosage used in humans. 
Macroporous scaffolds were prepared by robocasting of this mixture using a robotic deposition 
apparatus (EnvisionTEC GmbH Prefactory VR 3-D BioplotterTM). Previously, a stl model was 
designed as a cylinder with 14 mm in diameter, as previous experiments showed a volume reduction 
of 28 % in diameter after robocasting during the drying of the scaffolds. The scaffolds were printed  
by depositing the paste through a cylindrical nozzle (diameter = 460 m) at the volumetric flow rate 
required to maintain a constant x–y table speed of 5 mm·s
-1
 with a height increase between layers 
along z axis of 450 m. Each scaffold was robocasted with 25 layers, reaching an initial height of 
11.5 mm. A constant temperature of 25 ºC was kept in the paste reservoir and in the deposition 
plate.  Finally, the scaffolds were kept at 40ºC overnight to remove the rest of remaining 
dichloromethane. Cylindrical scaffolds with diameter of 10 mm, height of 10 mm and 415 (± 12) 
mg in weight, were obtained after complete solidification and drying. 
2.3. Physico-chemical characterization 
Textural properties of the scaffolds were determined by nitrogen adsorption with a Micromeritics 
3Flex equipment. Samples were previously degassed under vacuum for 24 h, at 40 °C. Differential 
thermal analysis was carried out using a TG/DTA Seiko SSC/5200 thermobalance between 50 ºC 
and 1000 °C at a heating rate of 1 ºC·min
-1
. Both, nitrogen adsorption and thermogravimetric 
analysis were carried out in triplicate. 
 The scaffolds surfaces were studied by Fourier transform infrared (FTIR) spectroscopy using a 
Nicolet Magma IR spectrometer and by scanning electron microscopy (SEM) using a JEOL F-6335 
microscope, operating at 20 kV and equipped with an energy dispersive X-ray spectrometer. 
2.4. Study of zoledronic acid release 
Since zoledronic acid is included in the raw -polycaprolactone-MBG mixture before printing the 




zoledronic acid is incorporated into the scaffolds, in the same manner than the other components, 
i.e. MBG and -polycaprolactone. Previously, the calibration curve for zoledronic acid in a 
phosphate buffer saline (PBS) at pH 7.4 and 37 °C was calculated by measuring the absorbance at 
209 nm of different solutions with concentrations between 0.001 mg/mL and 0.15 mg/mL. MBG-
PCL-zol scaffolds weighting 415 mg (± 12) containing 4 mg (±0.1) of zoledronic acid (1% in 
weight) were soaked in 2 mL of the PBS solution at 37ºC.  Continuous stirring was maintained 
during the delivery tests and the media was refreshed every time point. After 30 days soaked in 
PBS, the high deterioration of the scaffolds led us to stop the test. Zoledronic acid released was 
quantified in the supernatant using a Helios Zeta UV–vis spectrophotometer by reading the 
absorbance at 209 nm. 
2.5. Culture of human Saos-2 osteoblasts 
Human Saos-2 osteoblasts were cultured in the presence of MBG-PCL or MBG-PCL-zol scaffolds 
for 7 days in Dulbecco´s Modified Eagle´s Medium with 10% fetal bovine serum, L-glutamine and 
antibiotics. Cells were then harvested with 0.25% trypsin-EDTA, centrifuged and resuspended in 
fresh medium for the flow cytometric analysis of cell cycle and apoptosis quantification (see 
supporting information for further details).   
2.6. Osteoclast differentiation and resorption activity evaluation 
RAW-264.7 macrophages were seeded on glass coverslips in Minimum Essential Medium Eagle 
Alpha Modification with 5% fetal bovine serum, L-glutamine, antibiotics, 40 ng/mL of mouse 
recombinant receptor activator for nuclear factor κ B ligand and 25 ng/mL recombinant human 
macrophage-colony stimulating factor for 7 days. MBG-PCL and MBG-PCL-zol scaffolds were 
immersed in the medium of osteoclast cultures from either the first day or the sixth day of 
differentiation until the seventh day. F-actin filaments were stained with rhodamine phalloidin and 
cell nuclei with 4′-6-diamidino-2′-phenylindole. Then, cells were examined by confocal laser 




osteoclasts was evaluated on the surface of nanocrystalline hydroxyapatite (nano-HA) disks. Nano-
HA disks were prepared by controlled precipitation of calcium and phosphate salts and 
subsequently heated at temperatures below the sintering point, as previously described [56]. After 7 
days of differentiation, cells were detached, and the geometry of resorption cavities produced by 
osteoclasts on the surface of nano-HA disks was observed by scanning electron microscopy (see 
supporting information for further details). 
2.7. In vivo studies in osteoporotic sheep model 
This study was approved by our Institutional Ethical Committee following the guidelines of the 
current normative (Directive 2010/63/EU of the European Parliament and of the Council of 
September 22, 2010, on the protection of animals used for scientific purposes). 
2.7.1. Induction of osteoporotic model 
Six 4-year-old female Merino sheep (mean preoperative weight of 43.78 ± 5.9 Kg) were included in 
the study, and all of them were operated on to place as previously reported [57]. Briefly, analgesia 
was achieved with ketorolac (1mg/kg) and buprenorphine (0.01mg/kg) and the sheep were 
ovarictomiced by lateral laparoscopy, fed with a calcium depleted diet (0.5 %) and treated with 
corticosteroids (500 mg methylprednisolone via intramuscular injection every 3 weeks). See 
supporting material for a detailed information of the procedure.  
2.7.2. Implantation surgical procedure 
Six months after the ovariectomy, the scaffolds were blindly implanted in the sheep under aseptic 
conditions and the same anaesthetic protocol described elsewhere [57] (see supporting information). 
The scaffolds were sterilized with formaldehyde vapors, in a steam sterilizer Matachana S.A. for 
hospital material sterilization and implanted for 12 weeks before being extracted for histological 
processing. Cylindrical defects (10 x 13 mm in size) were drilled at different locations and one 
empty defect were left as control (see supporting information for further surgical details).  




The bone segments containing the defect were dissected out and fixed by immersion in 96% 
ethanol. Bone segments were divided into 2 segments of 5 mm-thick slices with an automatic 
stainless-steel special saw for bone, and post-fixed in the same fixative for another 15 days. Half of 
the bone slices obtained were then fixed in formaldehyde for 3 days and then submerged in a 
decalcifier solution for 24 hours. (Leica Surgipath decalcifier II).  Once decalcified, bone slices 
were processed and embedded in paraffin in an automated tissue processor (Peloris II Tissue 
Processor. Leika Biosistems) we made a tissue block with each bone slice. Of each paraffin block 
we obtained two 5 µm-thick histological sections that were stained with Hematoxylin-Eosin 
(Agilent Dako Coverstainer for H&E). 
2.7.4. Image acquisition and analysis 
Images were obtained with a Leica DMD1008 and an Olympus BX40 microscopes and analysed 
with ImageJ 1.x to calculate defect area and bone ingrowth area in each section, as well as number 
of blood vessels. Histomorphometric quantification of bone ingrowth, inflammatory component and 
blood vessels density (table 1) was carried out by a blind reviewer (MSP). For histological 
evaluation, three sections of each sample were evaluated. 
For the evaluation of inflammatory component, a five graded scale based on the density and 
distribution (absent/mild/moderate/marked/ very marked, scored 0 to 4) was used. In the case of 
extent of vascularization, we used a four graded scale based on the density of blood vessels 
(absent/mild/moderate/marked/, scored 0 to 3) of vascularity. Initially, we scanned the H&E slide at 
low power magnification (x4), we identified the 3 hot spots with the higher vascular density, and we 
counted the number of vessels per 20X magnification field. (Olympus BX40). 
2.8. Statistics 
Data are expressed as means + standard deviations of a representative of three repetitive 
experiments carried out in triplicate. Statistical analysis was performed by using the Statistical 




analysis of variance (ANOVA). Scheffé test was used for post hoc evaluations of differences among 
groups. In all statistical evaluations, p < 0.05 was considered as statistically significant. 
3. Results  
3.1. Physicochemical characterization 
SEM micrographs (Figures 1a and b) show cylindrical scaffolds with a regular porous tetragonal 
structure with pores of 1 mm in size and struts of 400-500 m in thickness. Thermogravimetric 
analysis indicated 39 (±2) % in weight of -polycaprolactone and FTIR spectra showed the 
corresponding absorption bands of both MBG and polymer (Figure S1 in supporting information) 
3.2 In vitro drug release test. 
The in vitro release of zoledronic acid from MBG-PCL-zol scaffolds was followed for 30 days 
(Figure 2).  The release profile shows a slow delivery during the first 27 days, reaching 28 % of 
drug content. After this period, the zoledronic acid release is fostered, reaching values above 50 % 
after 30 days in PBS. 
The changes occurred on the scaffolds surface during the test were followed by SEM (Figure 3). 
Before soaking in PBS (Figure 3a), the surface of the struts appears coated by a continuous phase 
assignable to ɛ-PCL, which covers a second discrete phase (MBG particles). Only occasionally, 
MBG particles are exposed through the very scarce porosity of the struts surface. After 21 days 
(Figure 3b), the surface appearance has significantly changed. The micrograph shows more porosity 
and evidences that most of the continuous phase at the surface has disappeared, thus allowing the 
MBGs particles to be in contact with the surrounding fluid. After 30 days (figure 3c), the extent in 
which polymer has degraded is higher and leads to detachments at the contact points between rods 
(figure 3c), where the broken fibres of ɛ-PCL can be observed. 
The N2 adsorption-desorption isotherms profile (Figure 3d) and textural parameters (table 2) 
indicate that MBG-PCL-zol scaffolds has a very low surface area and porosity. These data agree 




-PCL. After 30 days in PBS, N2 isotherms profiles changed associated with to an increase of 
surface and porosity.  
3.3. In vitro cell culture tests 
Figure 4 shows the percentages of cells within each cycle phase in all these conditions evidencing 
that no alterations were detected in the G0/G1 and S phases in the presence of MBG-PCL or MBG-
PCL-zol scaffolds. However, MBG-PCL-zol scaffolds induced a significant increase (p < 0.005) of 
SubG1 fraction (apoptotic cells) and a significant decrease of G2/M phase (p<0.005). These results 
evidence that zoledronic acid released from MBG-PCL-zol samples produced osteoblast apoptosis 
accompanied by a delay of osteoblast proliferation, which is reflected by the decrease of G2/M 
percentage. 
Figure 5 shows the effects of MBG-PCL and MBG-PCL-zol scaffolds on the morphology of 
osteoclast-like cells observed by confocal microscopy after 7 days of differentiation. Multinucleated 
cells and actin rings were observed in the absence of scaffolds (Control in Figure 5a) and when 
MBG-PCL scaffolds were immersed in the culture medium from either the first day (Figure 5b) or 
the sixth day (Figure 5c) of differentiation until the seventh day, revealing osteoclast-like cell 
differentiation from RAW macrophages after 7 days in these conditions. Concerning MBG-PCL-zol 
scaffolds, a time dependent effect was observed. The presence of MBG-PCL-zol scaffolds from the 
first day of differentiation (Figure 5d) until the seventh day induced cell damage and osteoclast-like 
cells were not found in these cultures. However, when MBG-PCL-zol scaffolds were immersed in 
the medium from the sixth day of differentiation (Figure 5e) until the seventh day, multinucleated 
cells with actin ring were observed, thus evidencing that the presence of these scaffolds after the 
sixth day did not inhibit the osteoclastogenesis. 
The resorption cavities left by osteoclast-like cells on nanocrystalline hydroxyapatite disks were 
observed by SEM (Figure S2 in supporting information). Cavities of 20 to 30 micrometers in size 




MBG-PCL-zol scaffolds. The size of these cavities agrees with the size of the actin rings previously 
observed (Figure 5). 
3.4. Histological evaluation and histomorphometric quantification of bone ingrowth 
Histological examinations of bones after MBG-PCL implantation show the presence reparative 
trabecular bone from the peripheral host bone but also within the macroporous structure of the 
scaffold (Figure 6a). At higher magnification (Figure 6b) the histological observation of MBG-PCL 
also shows the presence of osteoblastic borders surrounding the newly-mineralized tissues, 
endothelial cells forming new vessels, multinucleated cells identified as osteoclasts and bone 
marrow. In the case of MBG-PCL-zol, the histological observation showed the infiltration of 
fibrotic tissue (figure 6c) and a large amount of inflammatory component associated to the scaffold 
surface (figure 6d). 
Figure 7a shows the extent in which new bone formation occurs in the control defect as well as in 
the presence of both type of scaffolds. In control defect, no significant new bone formation could be 
observed in the inner part of the defect (Figure S5 in supporting information), pointing out that bone 
regeneration is not possible after 12 weeks in the osteoporotic model used in this work. The 
implantation of MBG-PCL scaffolds not only provokes a statistically significant increase in bone 
formation at the defect site, but also a significant increase of the trabecular thickness (figure 7b). In 
the case MBG-PCL-zol scaffolds, the ossification of the defect is almost equivalent to that observed 
for control defects in both bone volume formation and trabecular thickness, i. e. only new bone 
formation appeared in the gap between the host bone and the implant, whereas the inner part of the 
scaffold is colonized by fibrous tissue. 
The scaffolds were scored for the presence of osteoblasts and osteoclasts within their pores, as well 
as for inflammatory response and vascularization (table S1 in supporting information). Figure 8a 
shows the scoring results for the presence of osteoblasts within the scaffold pores. MBG-PCL 




scoring of osteoclast presence within the scaffold pores is shown in Figure 8b. At 12 weeks there 
was no difference between MBG-PCL and MBG-PCL-zol despite of the presence of zoledronic 
acid in the latter. Scoring of inflammatory response (Figure 8c) showed MBG-PCL-zol scaffolds to 
elicit an intense response (> 3), significantly higher compared with the low inflammatory response 
observed for MBG-PCL (around 1). Scoring of vascularization showed no significant differences in 
the scaffolds (Figure 8d). 
4. Discussion 
 
In this work we have designed and manufactured macroporous scaffolds by robocasting. SEM 
observations indicate that robocasting allows for obtaining scaffolds made of MBG and -PCL in an 
accurate and reproducible manner. In this composite system, MBG provides the osteogenic 
properties to the scaffolds, whereas PCL acts as a binder during the scaffolds manufacture and 
reduces the brittleness of the pure MBG scaffolds. For this reason, our aim was to introduce the 
maximum amount of MBG but keeping the rheological characteristics of the injecting paste and 
preserving mechanical properties strong enough to handle the scaffolds during the surgery. This 
ratio was MBG:PCL 60:40 used in this work.  
SEM observations show that MBG-PCL scaffolds have a surface of continuous and smooth 
appearance. This fact could be due to the presence of a higher amount of polymeric -PCL, that 
covers MBG particles and occludes the intrinsic porosity of this bioactive glass. This heterogeneity 
in components distribution has been previously observed by Yun et al [35] and could be explained 
in terms of the kinetic evaporation of dichlorometane. Since -PCL solidifies insofar the solvent is 
evaporated, -PCL placed at the liquid-air interface solidifies faster than PCL entrapped within the 
inner part of the struts, leading to a phase separation with a PCL rich layer at the surface, as it can 
be seen in our SEM observation and confirmed by the dramatic surface reduction and porosity 




 -PCL is a relatively stable polymer in aqueous media due to its high degree of crystallinity and 
hydrophobicity. Its higher presence at the surface delays the drug release so that zoledronic acid is 
released very slowly during the first four weeks to the surrounded media. Once this external layer is 
partially degraded, zoledronic acid release is fostered. 
 The release of zoledronic acid has a considerable influence on osteoblast-like cells and osteoclasts. 
Our cell culture studies indicate that the incorporation of zoledronic acid in these scaffolds induced 
a significant increase of apoptosis in osteoblast-like cells and inhibits osteoclastogenesis, although 
this last effect could be only observed when osteoclast precursor cells were in contact with MBG-
PCL-zol scaffolds from the first day of study. This fact can be explained in terms of the release 
profile of zoledronic acid from MBG-PCL-zol scaffolds.  The drug release test in PBS showed that, 
after 24 hours in PBS, less than 2% of zoledronic acid had been released. In contact with osteoclast 
precursor cells (macrophages), this amount of drug seems to be not enough for inhibiting the 
differentiation towards osteoclast cells. After six days in contact with MBG-PCL-zol the amount of 
drug released (about 12 % of the payload) seems to be enough for damaging macrophages and for 
avoiding their differentiation to osteoclasts. However, although the presence of MBG-PCL-zol 
scaffolds from the first day until the seventh day induced cell damage on macrophages, the 
resorptive activity observed in this condition suggests that those macrophages that could survive 
were able to differentiate into osteoclast-like cells.   
The in vivo studies reveal that MBG-PCL scaffolds promotes bone regeneration in osteoporotic 
sheep, reaching higher ossification volume after 12 weeks and much larger trabecular thickness 
compared to the non-treated control defect. MBG-PCL scaffolds stimulated bone remodeling by 
providing a porous architecture that allows the formation of new bone, through the recruitment of 
osteoblasts even in the inner sites of the scaffolds. In addition, after the degradation of the external 




properties addressed by several authors [8,18] even under osteoporotic conditions. However, the 
regenerative properties of MBG-PCL scaffolds are lost after the incorporation of zoledronic acid. 
Our experiments demonstrate that zoledronic acid cannot be used as adjuvant therapy to bone grafts 
for the improvement of bone regeneration in skeletal defects. Contrarily to the beneficial effects 
described by other authors [42,44,45], in our case the local release of zoledronic acid elicits an 
intense inflammatory and fibrotic response, which impedes the formation of a calcified afibrilar 
phase required for new bone formation on implant surfaces. Certainly, Peter et al. [42] reported that 
the local release from the surface of non-porous titanium implants improves the osseointegration, as 
zoledronic acid increases the BDM of the surrounding host bone. In this case, zoledronic acid 
partially inhibits the osteoclast activity allowing this increase of BMD. However, the incorporation 
of zoledronic acid is deleterious for the regenerative properties of our MBG-PCL macroporous 
scaffolds. Our in vitro studies evidenced that it also affects to osteoblast like cells and would be also 
in agreement with the decrease of bone formation markers previously reported by Delmas et al [49]. 
In our experimental conditions, negative effects have been observed in both osteoclasts and 
osteoblasts due to zoledronic acid release from MBG-PCL-zol scaffolds. Recent studies show that 
this agent at micromolar doses produces negative effects on osteoblast viability, mineralization and 
collagen synthesis [58]. Concerning osteoclasts, it is known that zoledronic acid inhibits osteoclast 
proliferation and induces osteoclast apoptosis through the farnesyl diphosphate-mediated 
mevalonate pathway and caspase activation [59]. However, osteoclast precursors may develop 
resistance to zoledronic acid induced apoptosis through p38 MAPK-mediated pathway. It has been 
observed an enhanced effect of zoledronic acid on increasing the bone mineral density of 
ovariectomized mice as a consequence of inhibiting this pathway [59]. Concerning the doses of 
zoledronic acid used by other authors in vitro, osteoblasts were treated with 0.01-10 µM zoledronic 
acid [58] and osteoclasts were treated with 50-200 µM zoledronic acid [59]. In our studies, each 




reached would be 2 g/L in the case of total drug release, which corresponds to a concentration of 
700 µM zoledronic acid (MW 272.09). However, it is important to take into account that in our in 
vitro studies, after 7 days of culture, the zoledronic acid release from the scaffold into the culture 
medium is about 13% (Figure 2), which corresponds to 91 µM zoledronic acid. This amount is in 
the range of the doses used by other authors for in vitro studies with bone cells [58,59]. The drastic 
effects produced by MBG-PCL-zol scaffolds on osteoclasts could be due to an inhibition of  p38 
MAPK-mediated pathway and/or to the activation of the farnesyl diphosphate-mediated mevalonate 
pathway and caspase activation, although further experiments would be required to confirm this 
point. 
Our in vivo results indicate that local concentration of zoledronic acid is very high in the defect site. 
This could be due to an excessive amount of drug incorporated to the scaffolds, but also due to the 
macroporous architecture of the scaffolds that favors the local drug accumulation at the defect site. 
Regarding the amount of drug, each MBG-PCL-zol scaffold contains about 4 mg of zoledronic acid, 
which is a common dosage for intravenously infusions in humans. In this sense the loading of 
zoledronic acid in our scaffolds is not expected to have such a dramatical effects on sheep 
weighting around 50 Kg. Moreover, Verron et al [45] also observed bone augmentation and 
trabeculae reinforcement using a very similar animal model (osteoporotic sheep) and a much higher 
zoledronate amount (9.2 mg per implant) incorporated to an injectable mixture of calcium 
phosphate and cellulosic-derived hydrogel. Therefore, doses of 4 mg should not be very high 
according to other studies and the reasons for this local overdose could be found in the macroporous 
architecture of the scaffolds. In the case of non-porous implants, drug diffuses from the implant 
surface towards the surrounding host tissue. Insofar drug is released, a concentration gradient 
occurs between the implant surface and the peripheral tissues, in such a way that drug concentration 
decreases with the distance to the implant. Interestingly, it has been reported that bone tissue in 




whereas trabeculae at 200 m away from the implant showed larger trabeculae thickness [44]. In 
the case of our macroporous scaffolds implanted in a hollow defect, zoledronic acid is not only 
released towards the surrounding tissues but also inwards the hollow defect, so that local 
concentration increases insofar the drug is released. The local overdose reached in this situation 
would explain the intense inflammatory response observed in our experiments for MBG-PCL-zol 
scaffolds. This inflammatory response agrees with the arthralgias observed in some patients as side 
effects or because of overdosage with zoledronic acid [60]. Summarizing, whereas implantation of 
MBG-PCL macroporous scaffolds is an excellent strategy for bone regeneration even in 
osteoporotic environment, the incorporation of zoledronic acid is a counter-productive strategy. 
This is due to the partial inhibition of bone formation associated to zoledronic acid together with the 
porous architecture of the MBG-PCL scaffolds, which facilitates the local overdose of the drug 
within the defect. While this strategy can be useful to improve the fixation of non-porous orthopedic 
devices, it must be discarded for bone grafts designed for regeneration purposes.  
5. Conclusions 
MBG-PCL macroporous scaffolds have been prepared by robocasting for bone regeneration 
purposes. These scaffolds exhibit excellent biocompatibility under both in vitro and in vivo 
conditions. In this sense, MBG-PCL scaffolds stimulate bone regeneration in a scenario of 
osteoporosis. These implants promote new bone formation even when the site morphological and 
metabolic conditions are not favorable to osteointegration and subsequent regeneration. 
In order to evaluate the effects of the local release of an antiresorptive drug in bone defects, 
zoledronic acid was added to the scaffolds. The drug inhibits macrophage differentiation into 
osteoclasts but also induced apoptosis in osteoblast-like cells. Under in vivo conditions, the 
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Figure 1. Scanning electron micrographs of MBG-PCL-zol scaffolds. (a) magnification x 7 and (b) 
magnification x 20. 
Figure 2. Zoledronic acid release from MBG-PCL-zol as a function of soaking time. 
Figure 3. Scanning electron micrographs of MBG-PCL-zol scaffolds before (a) and after 21 days 
(b) and 30 days (c) of drug release test. Nitrogen adsorption/desorption isotherms of MBG-PCL-zol 
scaffolds before and after 30 days soaked in PBS (d). 
Figure 4. Effects of MBG-PCL (grey) and MBG-PCL-zol (black) scaffolds on cell cycle phases of 
human Saos-2 osteoblasts after 7 days of culture. Controls in the absence of scaffolds (white) were 
carried out in parallel. Statistical significance: *** p < 0.005. 
Figure 5. Effects of MBG-PCL and MBG-PCL-zol scaffolds on the morphology of osteoclast-like 
cells observed by confocal microscopy after 7 days of differentiation. (a)  Controls in the absence of 
scaffolds; (b) MBG-PCL scaffolds immersed in the medium of osteoclast cultures from the first 
day; (c) MBG-PCL scaffolds immersed in the medium of osteoclast cultures from the sixth day; (d) 
MBG-PCL-zol scaffolds immersed in the medium of osteoclast cultures from the first day; (e) 
MBG-PCL-zol scaffolds immersed in the medium of osteoclast cultures from the sixth day. Actin 
was stained with rhodamine-phalloidin (red) and cell nuclei with DAPI (blue). 
Figure 6. Histological examination after 12 weeks of implantation of MBG-PCL (a and b) and 
MBG-PCL-zol (c and d). The inset in figure 6.b shows osteoblast border (1), blood vessel (2) and 
osteoclast cells (3). (*) indicates inflammatory component.   
Figure 7. Histomorphometrical studies of bones of osteoporotic sheep. (a) Ossification volume, (b) 
trabeculae thickness. Statistical significance * p < 0.005 
Figure 8. Results of histological scoring. Scores for (a) the presence of osteoblasts at the scaffolds 
porosity, (b) the presence of osteoclasts at the scaffolds porosity, (c) the amount of inflammatory 





















































STATEMENT OF SIGNIFICANCE 
In addition to an increase in bone fragility and susceptibility to fracture, osteoporosis 
also hinders the clinical success of endosseous implants and grafting materials for the 
treatment of bone defects. For the first time, macroporous scaffolds made of 
mesoporous bioactive glass and -caprolactone have been evaluated in a sheep model 
that mimics the osteoporosis conditions in humans. These implants fostered bone 
regeneration, promoting new bone formation at both the peripheral and the inner parts 
of the scaffolds, showing  thick trabeculae and a high vascularization degree. Our 
results indicate that macroporous structures containing highly bioactive mesoporous 

















































Scoring for the extent of inflammatory component  
Description Score 
Absent 0 
Mild. Mild or moderate focal infiltrate, or mild multifocal 
infiltrate 
1 
Moderate. Marked focal, moderate or marked multifocal, 
or mild diffuse infiltrate grade 
2 
Marked. Moderate  diffuse infiltrate 3 
Very Marked. Marked diffuse infiltrate 4 
  
Scoring for the extent of blood vessels formation  
Description Score 
Absent 0 
Mild: 0-5 vessels /20X microscope field 1 
Moderate: 5-10 vessels /20X microscope field 2 
Marked >10 vessels / 20X microscope field 3 
  




0 % of the pores contain osteoblasts/osteoclasts 0 
1-24% of the pores contain osteoblasts/osteoclasts 1 
25-49% of the pores contain osteoblasts/osteoclasts 2 
50-74% of the pores contain osteoblasts/osteoclasts 3 




Table 2. Surface area, pore size and pore volume of MBG-PCL-zol before and after 






















(30 days in PBS) 
13.7 
(±1.2) 
18.2 
(±1.3) 
0.040 
(±0.011) 
 
 
 
